header logo image


Page 382«..1020..381382383384..390400..»

People with Heroin Addiction Have Unique Molecular Alterations to The Brain That Resemble Brain Disturbances Seen in Neurodegenerative Disorders Like…

September 15th, 2020 11:02 am

MEDIA ADVISORY

FOR IMMEDIATE RELEASE: Nature Communications: Published Monday, September 14, 2020

Newswise Corresponding Author:Yasmin Hurd, PhD, Director of The Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, and other coauthors.

Bottom Line:Herion-addicted individuals have alterations in the expression a gene called FYN - a gene known to regulate the production of Tau, a protein that is highly elevated and implicated in neurocognitive disorders like Alzheimers disease. The study emphasizes that opioid use can affect the brain in a way that might increase vulnerability of neural systems that trigger neurodegeneration later in life; however, since these changes are epigenetic (alterations in gene function that are influenced by environmental factors and not alterations of the DNA itself), they are reversible and medications that have already been developed to target FYN for neurodegenerative disorders may be studied as a novel treatment for opioid addiction.

Results:Interestingly, findings were consistent across human, animal and cell models. Through post-mortem analysis of the brains of human heroin users, the team found that, specifically in neurons, the most significantly impaired epigenetic region is related to a gene called FYN. Essentially, heroin opened up the DNA at the FYN gene, which encodes a protein called tyrosine kinase FYN, that is strongly linked to synaptic plasticity and which directly results in production of Tau. Too much Tau in the brain is associated with neurodegenerative diseases. They observed that expression and activity of tyrosine kinase FYN was also induced in rats trained to self-administer heroin and also in primary striatal neurons treated with chronic morphine in vitro. Additionally, they demonstrated that inhibition of the FYN kinase (either via pharmacological means or through genetic manipulation) reduces heroin-seeking and heroin-taking behaviors.

Why the Research Is Interesting:The findings will increase awareness about the potential impact of heroin to alter neural systems related to neurodegenerative disorders. The findings also identify FYN inhibitors as a novel therapeutic treatment for heroin use disorders.

Who: Human brains from a cohort of subjects who succumbed to heroin overdose and normal controls, translational animal model of rats trained to self-administer heroin, and primary striatal neurons treated with chronic morphine in vitro.

When: Adult animals were exposed to heroin and their brains studied.

What:They performed unbiased, cell-type-specific, genome-wide profiling of chromatin accessibility, providing insights into epigenetic regulation directly in the brains of heroin-addicted individuals. To assess the causal relationship between heroin use and FYN pathology, they studied the brains of rats trained to self-administer heroin and they hit primary striatal neurons with chronic morphine in petri dishes to examine the effect at the individual cellular level.

Study Conclusions:By scanning the entire genome of heroin users to identify whether disturbances in how genes are turned on or off exist, Mount Sinai researchers found that heroin opened up the DNA at the FYN gene. The FYN gene is known to regulate the production of Tau, a protein implicated in neurodegenerative disorder like Alzheimers disease, meaning that heroin may put users at an increased risk of neurodegenerative disease later in life. Importantly, these novel findings suggest that FYN inhibitors (which have already been developed and are being assessed for use in Alzheimers disease) may be promising therapeutic tools for heroin-use disorder.

Paper Title: Chromatin accessibility mapping of the striatum identifies tyrosine kinase FYN as a therapeutic target for heroin use disorder

Said Mount Sinai's Dr. Yasmin Hurd of the research: Drug overdoses due to opioid abuse remain at epidemic levels and continue to rise precipitously during the current pandemic, with novel treatments desperately needed. Direct molecular insights into the heroin-addicted human brain are critical to guide future therapies. Our new study findings clearly open up new lines of treatment opportunities for opioid use disorder, which could benefit and potentially save the lives of so many.

###

Here is the original post:
People with Heroin Addiction Have Unique Molecular Alterations to The Brain That Resemble Brain Disturbances Seen in Neurodegenerative Disorders Like...

Read More...

Houston, We Have an Eye Problem – Duke Today

September 15th, 2020 11:02 am

Image credit: NASA

Duke researchers team up with NASA to explore gene-environment interactions in astronauts

By Alexis Kessenich

Astronauts on long-duration spaceflights (LDSF) face a number of risks to their health some more obvious that others like during dynamic events such as launch and landing. But there are also lesser-known dangers, such as spaceflight-associated neuro-ocular syndrome (SANS), a spectrum of physiologic and pathologic neuro-ophthalmic changes that include swelling of the optic disc, nerve damage and vision impairment.

An astronauts susceptibility of developing SANS remains largely unknown, but a team of researchers in the Center for Applied Genomics and Precision Medicine (CAGPM) is on a mission to discover what causes the predisposition.

The Nutritional Biochemistry Laboratory at NASAs Johnson Space Center, led byScott M. Smith, completed preliminary studies and found metabolomics and geneticdifferencesin astronauts who developed SANS. This ledto a broader evaluation of genetics, so the team at CAGPM engaged to help.

Rachel MyersandRicardo Henaowill lead the studys data science efforts.

Were exploring over 80 genes associated with these metabolic pathways and around 500 different genetic variants within those genes, says Rachel Myers, lead analyst for the study. Our team will test each to see if one or groups of these variants are associated with SANS.

The study is comprised of three different cohorts: one pre- and post-spaceflight cohort and two cohorts mimicking SANS and spaceflight environments on Earth.

For the first cohort, data, such as eye measurements, were collected from astronauts before and after an LDSF. For the second cohort, data will be collected from patients at the Mayo Clinic with polycystic ovary syndrome, which shares some characteristics with SANS. The third cohort is a 30-day head-down tilt bedrest study, which mimics spaceflight environments and has been shown to inflict similar ocular changes.

Because the sample size is so small, and the number of astronauts available to participate is limited, the team will look at ways to combine different variants together and test association with the phenotypes provided by NASAs preliminary study to see if they can find what causes the predisposition.

No one has ever looked at the genetic aspect of SANS before. Its going to be really interesting to explore non-traditional approaches for genetic associations, adds Myers.

At the end of the study, the team hopes to have both an understanding of what the genetic landscape of SANS is and a sense of what approaches are going to work for further investigation.

With a small cohort, we run the risk of finding something thats completely random, says Myers, so well do additional validation after our initial findings before making recommendations.

Ultimately, were exploring gene-environment interactions, addsGeoff Ginsburg, principal investigator on the study. The astronauts exposures in space from ionizing radiation and microgravity to extreme social isolation presents an exciting scientific opportunity to understand how this intense and hostile environment interacts with our genomes.

Myers says after the study the team also hopes to have a new pipeline in the Center for processing sequencing data to get genetic variants, which will help with future studies.

A solution for these astronauts is hopefully on the horizon. But, for now, the project is one small leap for CAGPM, one giant leap for genetic research!

Association of Genetics and B Vitamin Status With the Magnitude of Optic Disc Edema During 30-Day Strict Head-Down Tilt Bed RestAstronaut ophthalmic syndromeGenotype, Bvitamin status, and androgens affect spaceflightinduced ophthalmic changesSpaceflight-related ocular changes:the potential role of genetics, and the potential ofB vitaminsas a countermeasure

Originally posted here:
Houston, We Have an Eye Problem - Duke Today

Read More...

Increase in Frequency of Product Innovations to Drive the Tooth Regenerations Market from 2018 to 2026 – Lake Shore Gazette

September 15th, 2020 11:00 am

The tooth is a biological organ and consists of multiple tissues including the cementum, dentin, enamel, and pulp. Dental caries, Periodontal disease, and tooth fracture are the three main factor for tooth loss. Tooth Regeneration is the specialty concerned with the treatment of dental diseases such as a cavity, periodontal disease and fracture of the tooth. Dental caries is also known as tooth decay is the main oral health problems in most of the industrialized countries. Facial trauma also the major cause of tooth loss. Tooth loss leads to people mentally and physically disturb and it also affect the self-confidence and quality of life. Tooth regeneration is the process of individual tissue and the whole tooth development. Basically, it is the process of restoring the loss of natural teeth. Tooth regeneration is stem cell-based regenerative medical procedure which is used in stem cell biology sector and tissue engineering. There are two approaches used in the build of new whole teeth, in vivo implantation of tooth germ cells which were previously generated from stem cells and grow in vitro cells and another organotypic culture is an appropriate technique for the generation of teeth. The process of tooth regeneration imitates the natural tooth development using stem cells. In another way instead of whole teeth regeneration, Different part of the teeth regenerates such as Enamel regeneration, Dentin regeneration, Pulp regeneration, and periodontal regeneration.

Globally increasing incidence and prevalence of dental problems such as a cavity, periodontal disease, and tooth fracture are the major factors driving the growth of the Tooth Regenerations market. Innovative new techniques in Tooth regeneration such as cell homing, cell transplantation is expected to increase the acceptance of Tooth Regenerations. Tooth regeneration not only regrowth the entire tooth but also the restoration of individual components of the tooth such as dentin, cementum, enamel and dental pulp and these individual regeneration process is anticipate the boost the market growth of tooth regeneration market. Dental implantation also increases the growth of tooth regeneration market. People are very keen interested in the tooth regeneration and they are also giving more importance to the aesthetic aspects of dental products, which is expected to increase the Tooth Regenerations and dental market over the forecast period. The increasing demand for a customized Tooth Regeneration with the specifications and other dental decorative installations is the key factor anticipated to propel the demand for Tooth Regenerations worldwide.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/26263

The Global Tooth Regenerations market is segmented on the basis of application, Demographics, technique and by End user

Based on the Application type Tooth Regenerations market is segmented as:

Based on the Demographic Tooth Regenerations market is segmented as:

Based on the Technique, Tooth Regenerations market is segmented as:

Based on the end user Tooth Regenerations market is segmented as:

According to WHO, approx.30% the geriatric population is affected by the complete loss of teeth. Rapidly increasing Dental cavities and periodontal diseases are the major drivers in the Tooth Regenerations market. The global Tooth Regenerations market by application is expected to be dominated the market of Tooth Regenerations, out of which Enamel segment is expected to generate maximum revenue share over the forecast period. By end user, Tooth Regenerations market is expected to be dominated by dental clinics and hospitals. The manufacturers in the concerned market are focusing on manufacturing advanced products for better patient compliance and make the procedure easier. The market of tooth regeneration is anticipated to boost by stem cell regeneration technology

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/26263

The global Tooth Regenerations market is expected to be dominated by North America due to higher adoption and significant geriatrics population which also increase the demand for dental service for Dental caries and Periodontal disease. Europe is expected to be the second most lucrative Tooth Regenerations market due to rising funds for research for the growing patient population. Asia-Pacific is expected to be the fastest growing Tooth Regenerations market due to rapidly increasing incidence of dental surgery, general prosthetic fixation. Latin America and Middle East & Africa are expected to be the least lucrative market due to Low awareness regarding the use of Tooth Regenerations technology and comparatively less developed healthcare infrastructure in major regions.

Examples of some of the market participants in the global Tooth Regenerations market identified are DENTSPLY Implant, Unilever, Datum Dental, Institut Straumann AG, Keystone Dental, Inc., Zimmer Biomet, Wright Medical Group N.V., Integra LifeSciences, CryoLife, Inc, BioMimetic Therapeutics, Inc, Cook Group and among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/26263

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

See the original post here:
Increase in Frequency of Product Innovations to Drive the Tooth Regenerations Market from 2018 to 2026 - Lake Shore Gazette

Read More...

Incremental Sales to Drive the Tooth Regenerations Market from 2018 to 2026 – Lake Shore Gazette

September 15th, 2020 11:00 am

The tooth is a biological organ and consists of multiple tissues including the cementum, dentin, enamel, and pulp. Dental caries, Periodontal disease, and tooth fracture are the three main factor for tooth loss. Tooth Regeneration is the specialty concerned with the treatment of dental diseases such as a cavity, periodontal disease and fracture of the tooth. Dental caries is also known as tooth decay is the main oral health problems in most of the industrialized countries. Facial trauma also the major cause of tooth loss. Tooth loss leads to people mentally and physically disturb and it also affect the self-confidence and quality of life. Tooth regeneration is the process of individual tissue and the whole tooth development. Basically, it is the process of restoring the loss of natural teeth. Tooth regeneration is stem cell-based regenerative medical procedure which is used in stem cell biology sector and tissue engineering. There are two approaches used in the build of new whole teeth, in vivo implantation of tooth germ cells which were previously generated from stem cells and grow in vitro cells and another organotypic culture is an appropriate technique for the generation of teeth. The process of tooth regeneration imitates the natural tooth development using stem cells. In another way instead of whole teeth regeneration, Different part of the teeth regenerates such as Enamel regeneration, Dentin regeneration, Pulp regeneration, and periodontal regeneration.

Globally increasing incidence and prevalence of dental problems such as a cavity, periodontal disease, and tooth fracture are the major factors driving the growth of the Tooth Regenerations market. Innovative new techniques in Tooth regeneration such as cell homing, cell transplantation is expected to increase the acceptance of Tooth Regenerations. Tooth regeneration not only regrowth the entire tooth but also the restoration of individual components of the tooth such as dentin, cementum, enamel and dental pulp and these individual regeneration process is anticipate the boost the market growth of tooth regeneration market. Dental implantation also increases the growth of tooth regeneration market. People are very keen interested in the tooth regeneration and they are also giving more importance to the aesthetic aspects of dental products, which is expected to increase the Tooth Regenerations and dental market over the forecast period. The increasing demand for a customized Tooth Regeneration with the specifications and other dental decorative installations is the key factor anticipated to propel the demand for Tooth Regenerations worldwide.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/26263

The Global Tooth Regenerations market is segmented on the basis of application, Demographics, technique and by End user

Based on the Application type Tooth Regenerations market is segmented as:

Based on the Demographic Tooth Regenerations market is segmented as:

Based on the Technique, Tooth Regenerations market is segmented as:

Based on the end user Tooth Regenerations market is segmented as:

According to WHO, approx.30% the geriatric population is affected by the complete loss of teeth. Rapidly increasing Dental cavities and periodontal diseases are the major drivers in the Tooth Regenerations market. The global Tooth Regenerations market by application is expected to be dominated the market of Tooth Regenerations, out of which Enamel segment is expected to generate maximum revenue share over the forecast period. By end user, Tooth Regenerations market is expected to be dominated by dental clinics and hospitals. The manufacturers in the concerned market are focusing on manufacturing advanced products for better patient compliance and make the procedure easier. The market of tooth regeneration is anticipated to boost by stem cell regeneration technology

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/26263

The global Tooth Regenerations market is expected to be dominated by North America due to higher adoption and significant geriatrics population which also increase the demand for dental service for Dental caries and Periodontal disease. Europe is expected to be the second most lucrative Tooth Regenerations market due to rising funds for research for the growing patient population. Asia-Pacific is expected to be the fastest growing Tooth Regenerations market due to rapidly increasing incidence of dental surgery, general prosthetic fixation. Latin America and Middle East & Africa are expected to be the least lucrative market due to Low awareness regarding the use of Tooth Regenerations technology and comparatively less developed healthcare infrastructure in major regions.

Examples of some of the market participants in the global Tooth Regenerations market identified are DENTSPLY Implant, Unilever, Datum Dental, Institut Straumann AG, Keystone Dental, Inc., Zimmer Biomet, Wright Medical Group N.V., Integra LifeSciences, CryoLife, Inc, BioMimetic Therapeutics, Inc, Cook Group and among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/26263

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

Link:
Incremental Sales to Drive the Tooth Regenerations Market from 2018 to 2026 - Lake Shore Gazette

Read More...

New molecular therapeutics center established at MIT’s McGovern Institute – MIT News

September 15th, 2020 10:59 am

More than 1 million Americans are diagnosed with a chronic brain disorder each year, yet effective treatments for most complex brain disorders are inadequate or even nonexistent.

A major new research effort at the McGovern Institute for Brain Research at MIT aims to change how we treat brain disorders by developing innovative molecular tools that precisely target dysfunctional genetic, molecular, and circuit pathways.

The K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience was established at MIT through a $28 million gift from philanthropist Lisa Yang and MIT alumnus Hock Tan 75. Yang is a former investment banker who has devoted much of her time to advocacy for individuals with disabilities and autism spectrum disorders. Tan is president and CEO of Broadcom, a global technology infrastructure company.This latest gift brings Yang and Tans total philanthropy to MIT to more than $72 million.

In the best MIT spirit, Lisa and Hock have always focused their generosity on insights that lead to real impact," says MIT President L. Rafael Reif. Scientifically, we stand at a moment when the tools and insights to make progress against major brain disorders are finally within reach. By accelerating the development of promising treatments, the new center opens the door to a hopeful new future for all those who suffer from these disorders and those who love them. I am deeply grateful to Lisa and Hock for making MIT the home of this pivotal research.

Engineering with precision

Research at the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience will initially focus on three major lines of investigation: genetic engineering using CRISPR tools, delivery of genetic and molecular cargo across the blood-brain barrier, and the translation of basic research into the clinical setting. The center will serve as a hub for researchers with backgrounds ranging from biological engineering and genetics to computer science and medicine.

Developing the next generation of molecular therapeutics demands collaboration among researchers with diverse backgrounds, says Robert Desimone, McGovern Institute director and the Doris and Don Berkey Professor of Neuroscience at MIT. I am confident that the multidisciplinary expertise convened by this center will revolutionize how we improve our health and fight disease in the coming decade. Although our initial focus will be on the brain and its relationship to the body, many of the new therapies could have other health applications.

There are an estimated 19,000 to 22,000 genes in the human genome and a third of those genes are active in the brain the highest proportion of genes expressed in any part of the body. Variations in genetic code have been linked to many complex brain disorders, including depression, Parkinsons, and autism. Emerging genetic technologies, such as the CRISPR gene editing platform pioneered by McGovern Investigator Feng Zhang, hold great potential in both targeting and fixing these errant genes. But the safe and effective delivery of this genetic cargo to the brain remains a challenge.

Researchers within the new Yang-Tan Center will improve and fine-tune CRISPR gene therapies and develop innovative ways of delivering gene therapy cargo into the brain and other organs. In addition, the center will leverage newly developed single-cell analysis technologies that are revealing cellular targets for modulating brain functions with unprecedented precision, opening the door for noninvasive neuromodulation as well as the development of medicines. The center will also focus on developing novel engineering approaches to delivering small molecules and proteins from the bloodstream into the brain. Desimone will direct the center and some of the initial research initiatives will be led by associate professor of materials science and engineering Polina Anikeeva; Ed Boyden, the Y. Eva Tan Professor in Neurotechnology at MIT; Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Brain and Cognitive Sciences at MIT; and Feng Zhang, James and Patricia Poitras Professor of Neuroscience at MIT.

Building a research hub

My goal in creating this center is to cement the Cambridge and Boston region as the global epicenter of next-generation therapeutics research. The novel ideas I have seen undertaken at MITs McGovern Institute and Broad Institute of MIT and Harvard leave no doubt in my mind that major therapeutic breakthroughs for mental illness, neurodegenerative disease, autism, and epilepsy are just around the corner, says Yang.

Center funding will also be earmarked to create the Y. Eva Tan Fellows program, named for Tan and Yangs daughter Eva, which will support fellowships for young neuroscientists and engineers eager to design revolutionary treatments for human diseases.

We want to build a strong pipeline for tomorrows scientists and neuroengineers, explains Hock Tan. We depend on the next generation of bright young minds to help improve the lives of people suffering from chronic illnesses, and I can think of no better place to provide the very best education and training than MIT.

The molecular therapeutics center is the second research center established by Yang and Tan at MIT. In 2017, they launched the Hock E. Tan and K. Lisa Yang Center for Autism Research, and, two years later, they created a sister center at Harvard Medical School, with the unique strengths of each institution converging toward a shared goal: understanding the basic biology of autism and how genetic and environmental influences converge to give rise to the condition, then translating those insights into novel treatment approaches.

All tools developed at the molecular therapeutics center will be shared globally with academic and clinical researchers with the goal of bringing one or more novel molecular tools to human clinical trials by 2025.

We are hopeful that our centers, located in the heart of the Cambridge-Boston biotech ecosystem, will spur further innovation and fuel critical new insights to our understanding of health and disease, says Yang.

See more here:
New molecular therapeutics center established at MIT's McGovern Institute - MIT News

Read More...

Whats Wrong With the Meritocracy – The New York Times

September 15th, 2020 10:59 am

What, he wonders, if the highly educated harden into a hereditary aristocracy? And what if this occurs under a flag of fairness, during a time when B.A.s and higher degrees are ever more closely tied to income and prestige? Lets set aside the case of rich parents who bribe corrupt officials or donate huge sums to get their child into a good college. Lets focus instead, Sandel writes, on the inequity that creeps in without breaking any rules. At Princeton and Yale, for example, more students come from families in the top 1 percent of income than from the bottom 60 percent. Two-thirds of students in all the Ivy League schools come from families in the top 20 percent. This is very largely because of the head start woven into upper-income life itself: engaging dinner conversation, better schools, private tutors, foreign travel.

Sandel is not about guilt-tripping anxious parents of front-row kids; theyre suffering too, he says. But the credentialed have come to imagine themselves as smarter, wiser, more tolerant and therefore more deserving of recognition and respect than the noncredentialed. One reason for this, he suggests, lies in our American rhetoric of rising. Both rich and poor parents tell their kids, if you try hard enough, you can achieve your goals. For the upper strata, things may work out, but for the downwardly mobile blue collar and poor, theres a Catch-22. If they fail to reach their goals which a torpid economy almost guarantees they blame themselves. If only I could have gotten that degree, they say. Even the poorly educated, Sandel notes, look down on the poorly educated.

Donald Trump has reached out to this group with open arms I love the poorly educated. He has harvested their demoralization, their grief and their shame, most certainly if they are white. But, Sandel notes, two-thirds of all American adults lack four-year degrees. And in the wake of automation, in real wages, the white man without a B.A. earns less now than he did in 1979. The dignity of his labor has steeply declined. And since 1965, high-school-educated men in the very prime of life 25 to 54 have been slipping out of the labor force, from 98 percent in 1965 to 85 percent in 2015. Of all Americans whose highest degree is a high school diploma, in 2017 only 68 percent worked. And with rising deaths of despair, many are giving up on life itself. So you who are highly educated, Sandel concludes, should understand that youre contributing to a resentment fueling the toxic politics you deplore. Respect the vast diversity of talents and contributions others make to this nation. Empathize with the undeserved shame of the less educated. Eat a little humble pie.

But we are left with an important issue Sandel does not address: the targeting by the right wing of colleges themselves. This isnt new: Running parallel to the rise of the meritocracy in America has been a suspicion of the egghead who cant skin a rabbit, build a house or change a tire. As the historian Richard Hofstadter observed in Anti-Intellectualism in American Life, and Tocqueville before him, many Americans have valued not simply the cultivated intelligence of heroes in a culture of merit but also the creative genius of the common man in a culture of survival.

Today this has taken a shockingly partisan turn. For the first time in recent history, the less education you have, the more you lean right and distrust higher education itself. In a 2019 Pew survey, 59 percent of Republicans (and Republican-leaning independents) agree that colleges have a negative effect on the way things are going in the country these days, whereas only 18 percent of Democrats (and those leaning left) agree.

Continue reading here:
Whats Wrong With the Meritocracy - The New York Times

Read More...

Can gene-edited crops be ‘detected’? Claims by Greenpeace and anti-biotech activists dismissed by safety officials, scientists – Genetic Literacy…

September 15th, 2020 10:59 am

A joint report by several NGOs caused a stir on September 7th by claiming that [gene editing] was now detectable by means of a laboratory test. This refutes the claim of genetic engineering proponents that plants produced using [gene editing] are indistinguishable from conventionally grown plants.

Among others, Greenpeace . funded a study conducted by researchers from Iowa who said they have developed a detection method that can be used to identify point mutations.

The Federal Office for Consumer Protection and Food Safety (BVL), as the licensing authority, took a closer look at this study. The BVL came to a significantly different conclusion than the anti-genetic engineering NGOs.

The herbicide tolerance trait in Cibus oilseed rape [used in the study] was the result of a point mutation. The BVL made it clear: These mutations can have very different origins: New breeding methods, such as genome editing, as well as classic breeding methods and random biological processes are all possible sources of such genetic changes.

According to the information available, the BVL comes to the conclusion that the point mutation considered in the article did not result from genome editing processes, the agency said.

In a more detailed analysis . the BVL stated that the named detection method is suitable for identifying this specific point mutation, but not whether it actually came about in one of the rapeseed lines through genome editing, BVL added in its statement.

This story was published in German and has been translated and edited for clarity.

Read the original post

Go here to see the original:
Can gene-edited crops be 'detected'? Claims by Greenpeace and anti-biotech activists dismissed by safety officials, scientists - Genetic Literacy...

Read More...

The growing demand for medical lab scientists and the ‘important role’ they play during COVID-19 – East Idaho News

September 15th, 2020 10:59 am

A former Idaho State University medical laboratory science student. | Courtesy Idaho State University

POCATELLO Medical laboratory scientists play an important role in helping keep the health care system running, but they dont often get credit for what they do because they work behind the scenes.

Idaho State Universitys Medical Laboratory Science Program Director Rachel Hulse explained that medical lab scientists are sometimes referred to as the doctors doctor. This is because they assist primary care providers in disease diagnosis.

Between 70% and 80% of all medical decisions that primary health care providers make are based on scientists lab findings.

Every tube of blood thats drawn, every body tissue, every urine or other kind of body fluid that might come out of the body, were the ones who are running the tests and the analyses on those to try to figure out whats going on, Hulse said.

Hulse says 100% of ISU graduates in the program are employed in the field or in a closely related field immediately after earning their degree.

ISUs medical laboratory science program is the only accredited program in the state of Idaho that offers both a bachelors and a masters degree, according to Hulse.

We actually have a huge workforce shortage, similar to what you hear about in nursing, Hulse explained. The number of graduates (nationally) cant fill the number of jobs that we have, and thats exacerbated now, by COVID, because theres an increased need for testing capacity.

It can be difficult for doctors to differentiate between a cold, flu or COVID-19 without doing laboratory diagnostic testing, she said. But even if the pandemic wasnt happening right now, testing is something that never goes away because people get sick and some have chronic health issues.

Before the onset of the pandemic, the profession was projected to grow between 10% and 16% within the next decade.

That is way above the national average for job growth, she said.

An article published on Genetic Engineering and Biotechnology News also noted that the job outlook for medical lab scientists over the next few years is growing much faster than average.

Courtesy Idaho State University

While the occupation is something Hulse doesnt believe is recognized enough, especially for being a massively critical part of the healthcare team, she feels COVID-19 has exposed the profession a little more, and the virus has helped students realize how essential and fulfilling the job is.

I think its so important to recognize the other pieces of the healthcare team that are so critical, not only in healthcare in general but in a pandemic setting, Hulse added. Its important to have an understanding of what those teams are and the options that (students) have.

The ISU medical laboratory science program can be taken online. Students in Alaska, rural parts of Idaho and other areas of the country have participated in the program.

The application for the program will open in October and is due at the end of February. Students who are admitted will start the program at the beginning of the following fall semester.

More information on the program can be found here.

Former students in Idaho State Universitys medical laboratory science program. | Courtesy Idaho State University

Read this article:
The growing demand for medical lab scientists and the 'important role' they play during COVID-19 - East Idaho News

Read More...

The limits of synthetic biology through the origins of SARS-CoV-2 – Drug Target Review

September 15th, 2020 10:59 am

Conspiracy theories about COVID-19 have been spreading since the early days of the outbreak. But how do we know whether a biological entity is artificially made or has occurred naturally? Marc Baiget Francesch explores the capabilities of current scientific approaches in terms of virus engineering and how this applies to the present pandemic.

OVER THE LAST few months, numerous theories relating to the origin of the novel coronavirus SARS-CoV-2 have invaded the internet. Sometimes, these theories can give rise to more interesting discussions than what is originally intended by the authors. For example, the theory that the new coronavirus has been purposely made as a biological weapon would mean that SARS-CoV-2 is a synthetic organism, which simultaneously implies that scientists can create synthetic viruses. How much truth is there in that implication? How far can current technologies go in terms of artificial microorganisms design? To answer these questions, we first need to understand the current state of synthetic biology as a field and acknowledge its limitations.

While making a new virus from scratch is not technically impossible, it would require a level of knowledge that is implausible to imagine in any scientific institution at present

Synthetic biology greatly relies on predictive models and computer simulated structures. Computer programmes use the information collected by years of research in molecular biology, which is stored in huge libraries of microorganisms, molecules and domains, to explore their potential when modified or combined in silico that is, on a computer. The idea of these programmes is to form combinations that, presumably, do not exist in nature in order to analyse potential structures for multiple uses. However, despite in silico models providing valuable information and saving time and money on in vitro experimentation, they are far from perfect.

Professor JA Davies, from the University of Edinburgh, published a paper in the open access journal Life that analysed the current flaws of the engineering approach in synthetic biology. While he recognises that this approach, based on the design-build-test dogma, is interesting and that relying on standard pre-existing parts simplifies the overall design of synthetic structures, it lacks biological understanding.1

In biology, every component from a microorganism has a metabolic cost, ie, the more components you add to a cell, the less energy the cell can direct to each part. Therefore, the fewer parts used for a function, the better. In genetic engineering this is a crucial consideration, since adding new genes normally supposes that pre-existing genes are deleted in order for the organism to be viable. In addition, the interactions between two different pre-existing parts might affect its original function. Hence, as Professor Davies argues, using a novel part, designed for a specific function, might prove easier than trying to reproduce the same function with two pre-existing ones. Ultimately, evolution is based on constant changes of previous structures induced by a huge number of factors and not on the combination of unchanging structures. So, while synthetic biology can cover a lot of unexplored possibilities, it is still far from being an almighty tool or competing with natural evolution.

This brings us to the next question: how capable are current scientific approaches in terms of virus engineering? Researchers can recreate an existing virus from scratch, and this is what many research teams have been attempting since the coronavirus started to spread in order to understand the virus better.2 However, creating a new one is another story. It is possible to create new viruses from original ones; though, there are some restrictions. As aforementioned, synthetic biology relies on the use of pre-existing parts, which means we would need to use different parts of existing viruses and assemble them in order to produce a new virus. Dr Robert F Garry, a microbiologist specialising in virology, commented in Business Insider that there is no consensus on what exactly makes a virus pathogenic.3 Therefore, while making a new virus from scratch is not technically impossible, it would require a level of knowledge that is implausible to imagine in any scientific institution at present. Nevertheless, our current knowledge of molecular science allows us to identify potentially man-made structures or microorganisms.4 This is possible because they are based on pre-existent parts; an engineered virus would have identifiable segments of DNA that belong to other viruses whose sequences are stored in libraries. This means that we should be able to identify if a new virus was artificially designed or is a product of natural evolution.

To study the case of the novel coronavirus, we need to have access to its genetic sequence. This has been a major advancement in epidemiology, as for previous pandemics researchers had to wait from months to years in order to study the microorganism responsible for the outbreak, whereas the structure of SARS-CoV-2 was available within weeks. By analysing its genetic structure, scientists have realised that the backbone of the virus is, indeed, a new one.5 However, this does not mean that the virus was not artificially made; we just know that the backbone was not copied from another virus.

What about prompting an existent virus to mutate? It could be that biotechnologists induced mutations to a known virus in order to produce a novel one, like what we see in nature. However, when scientists evaluated the structure of SARS-CoV-2 and compared it to other viral structures, the closest relative they found was SARS-CoV RaTG13, which showed a 96 percent similarity to the novel coronavirus.6 Although 96 percent may seem a lot, considering the size of SARS-CoV-2, which is close to 30,000 nucleotides long, this four percent difference is quite significant around 1,200 nucleotides.7

Studying evolution and natural processes is key for synthetic biology to expand and become an even more powerful tool

Nevertheless, there may still be some resistance to debunking certain theories. One might argue that, while using known parts of similar viruses, targeted mutations could have been applied to give the virus the ability to attach to human cells which is essentially what makes this virus able to infect humans. One of the most curious facts about the coronavirus is that the receptor binding domain the part that makes SARS-CoV-2 able to attach to human cells was simulated in silico once the sequence of the virus was made available. This sequence showed poor efficiency on the simulations, meaning that nature has found a mechanism that we had not been able to predict.3 If we put together all the facts and reflect on the fact that 75 percent of the new emerging diseases are from zoonotic origin, it appears the theories around SARS-CoV-2 being a man-made virus are quite unrealistic, to say the least.8

Something I have found interesting since the search of the origin of the SARS-CoV-2 started, is that we have confirmed that synthetic biology still has a long way to go. We still need to understand a lot about nature to get a bigger picture of how things work and to grasp all the possibilities that molecular biology has to offer. Studying the evolution of viruses not only benefits the epidemiologists, but also the synthetic biologists, who gain insights into how molecular interactions work. This newfound knowledge can be used to improve current models and propose frameworks for the creation of new molecules. Therefore, one can conclude that studying evolution and natural processes is key for synthetic biology to expand and become an even more powerful tool.

Marc Baiget Francesch is an MSc in Pharmaceutical Engineering and currently works as an Assistant Editor for the International Journal of Molecular Sciences. He also writes articles and innovation grants as a freelancer.

Excerpt from:
The limits of synthetic biology through the origins of SARS-CoV-2 - Drug Target Review

Read More...

Bio-weapon warning: Next pandemic could be genetically engineered, experts warn – Daily Express

September 15th, 2020 10:59 am

Terrorists could genetically modify diseases to attack their enemies, and the consequences would be far more devastating than an outbreak of natural origin, scientists believe. If terrorists were able to obtain the biotechnology which allowed them to genetically modify a pathogen or virus, the consequences could be deadly for humanity and it could be the root of the next major pandemic.

The world has struggled to cope with a virus outbreak of natural origins in the coronavirus pandemic, with almost one million dead.

However, if a new virus were to be engineered, it would be completely foreign to scientists who would ultimately struggle to be able to contain and find a cure.

Vivek Wadhwa from Harvard Law Schoool, said advancements in gene-editing technology such as CRISPR are making it easier to create bioweapons.

Much in the same way as vaccines are created by identifying the antigen which triggers the immune response which are then isolated and then injected it into humans a similar process could happen by identifying the lethal traits in viruses to make them even more harmful.

Mr Wadwha wrote in an essay for Foreign Policy: "With COVID-19 bringing Western economies to their knees, all the worlds dictators now know that pathogens can be as destructive as nuclear missiles.

"Whats even more worrying is that it no longer takes a sprawling government lab to engineer a virus.

"Thanks to a technological revolution in genetic engineering, all the tools needed to create a virus have become so cheap, simple, and readily available that any rogue scientist or college-age biohacker can use them, creating an even greater threat.

It is now too late to stop the global spread of these technologies the genie is out of the bottle.

READ MORE:Coronavirus conspiracy theory: Claims of bioweapons and the apocalypse

"We must treat the coronavirus pandemic as a full dress rehearsal of what is to come unfortunately, that includes not only viruses that erupt from nature, but also those that will be deliberately engineered by humans.

Mr Wadhwa is not the only expert concerned about the potential rise of bioterrorism.

Bryan Walsh, author of the book End Times which details the existential threats humanity faces, told Express.co.uk: When I look into the near future, the thing that worries me the most is the threat of a bioengineered pandemic created out the lab using some of these new tools for genetic editing.

"That is particularly dangerous because diseases and pandemics are a threat already but what could be created in a lab on purpose say by terrorists would be much worse than anything created by nature."

DON'T MISSBill Gates: Terrorists could kill TENS OF MILLIONS with BIOWEAPONSNext biological weapon FOUND? Insect ARMY being harnessed in the USWas this coronavirus PATIENT ZERO? Vicious bat attack at Chinese lab

Other scientists, however, are more optimistic about the benefits of CRISPR and other gene-editing tools.

Helen ONeill, a molecular geneticist at University College London, believes disease could one day be irradiated through genetic modification.

She said: There are endless capacities when it comes to gene editing.

We can take your blood cells, we fix them and reinsert them back in to you.

"Soon every baby will have every letter of its genome read on the day it is born so we can tailor medication for them.

View original post here:
Bio-weapon warning: Next pandemic could be genetically engineered, experts warn - Daily Express

Read More...

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2…

September 15th, 2020 10:59 am

GAITHERSBURG, Md., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax recombinant protein nanoparticle technology and includes Novavax proprietary MatrixM adjuvant.

Todays agreement with Serum Institute enhances Novavax commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents, said Stanley C. Erck, President and Chief Executive Officer of Novavax. We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks.

The agreement with SIIPL augments a global supply chain that will deliver over two billion doses of NVX-CoV2373 annually as of 2021.

The antigen component of NVX-CoV2373 is being manufactured at Novavax CZ in Bohumil, Czech Republic (formerly Praha Vaccines), as well as at the following partnered manufacturing sites:

Novavax Matrix-M adjuvant is now being manufactured at Novavax AB in Uppsala, Sweden and the following partnered manufacturing sites:

Signing of the manufacturing agreement with Novavax for NVX-CoV2373 is another great milestone for both companies, which will further strengthen our existing relationship. SIIPL expertise to scale-up and manufacture NVX-CoV2373 will help ensure the supply of this most-needed vaccine, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.

About NVX-CoV2373

NVXCoV2373 is a vaccine candidate engineered from the genetic sequence of SARSCoV2, the virus that causes COVID-19 disease. NVXCoV2373 was created using Novavax recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVXCoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1 portion of the Phase 1/2 clinical trial, NVXCoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. Phase 2 clinical trials began in August 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

About Matrix-M

Novavax patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.

About Serum Institute of India

Serum Institute of India Pvt. Ltd. was founded in 1966 by Dr. Cyrus Poonawalla with a mission of manufacturing life-saving immuno-biologics. Serum is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses). It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by Serum are accredited by the World Health Organization, Geneva and are being used in approximately 170 countries across the globe.

Serum is ranked as India's No. 1 biotechnology company, manufacturing highly specialized lifesaving biologics like vaccines using cutting edge genetic and cell-based technologies, antisera and other medical specialties.

The philanthropic philosophy of Serum continues with its work on newer vaccines and biologicals.

Learn more about Serum Institute of India at https://www.seruminstitute.com/.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil society organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated 9 partnerships to develop vaccines against the novel coronavirus. The programs will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.

Before the emergence of COVID-19 CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).

Novavax Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading Risk Factors in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 8-K for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Novavax

InvestorsSilvia Taylor and Erika Trahanir@novavax.com240-268-2022

MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659

More:
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax' Global Production Capacity to Over 2...

Read More...

Death by COVID: 5 immune response markers that predict whether an infected person is likely to survive – Genetic Literacy Project

September 15th, 2020 10:59 am

[Researchers] have identified five immune response markers that, collectively, were able to distinguish between those COVID-19 patients who convalesced from the infection, and those who didnt survive the disease. The researchers used a systems serology technique to generate a detailed profile of SARS-Co-2-specific humoralantibody generatingresponses in hospitalized patients, which they validated in a second patient cohort. The findings indicated that individuals who survived COVID-19 infection and those who died exhibited antibody responses that were primarily directed against different SARS-CoV-2 proteins.

By looking at the overall profile of the immune response, we can begin to truly understand how the immune system responds to COVID-19 and then use that knowledge to prevent the worst outcomes of this disease, [said researcher Galit Alter.]

Its still not clear why some individuals infected with SARS-CoV-2 recover from infection and others die, the authors noted. While the rapid spread of SARS-CoV-2, even during the asymptomatic phase of this infection, is alarming, more harrowing is our inability to predict disease trajectories among symptomatic individuals. And without any therapeutics or vaccines as countermeasures, there is an urgent need to start mapping how immunity to the virus starts to develop. This knowledge will not only help to guide patient care, but could help to direct the development of future immune-based strategies against the disorder.

Read the original post

Read more:
Death by COVID: 5 immune response markers that predict whether an infected person is likely to survive - Genetic Literacy Project

Read More...

Was COVID-19 Manmade? Meet the Scientist Behind the Theory – Boston magazine

September 15th, 2020 10:59 am

Research

The worlds preeminent scientists say a theory from the Broad Institutes Alina Chan is too wild to be believed. But when the theory is about the possibility of COVID being man-made, is this science or censorship?

Illustration by Benjamen Purvis

In January, as she watched the news about a novel virus spreading out of control in China, Alina Chan braced for a shutdown. The molecular biologist at the Broad Institute of Harvard and MIT started stockpiling medicine and supplies. By the time March rolled around and a quarantine seemed imminent, shed bought hundreds of dollars worth of fillets from her favorite fishmonger in Cambridge and packed them into her freezer. Then she began to ramp down her projects in the lab, isolating her experimental cells from their cultures and freezing them in small tubes.

As prepared as she was for the shutdown, though, she found herself unprepared for the frustration of being frozen out of work. She paced the walls of her tiny apartment feeling bored and useless. Chan has been a puzzle demon since childhood, which was precisely what she loved about her workthe chance to solve fiendishly difficult problems about how viruses operate and how, through gene therapy, they could be repurposed to help cure devastating genetic diseases. Staring out her window at the eerily quiet streets of her Inman Square neighborhood, she groaned at the thought that it could be months before she was at it again. Her mind wandered back to 2003, when she was a teenager growing up in Singapore and the first SARS virus, a close relative of this coronavirus, appeared in Asia. It hadnt been anything like this. That one had been relatively easy to corral. How had this virus come out of nowhere and shut down the planet? Why was it so different? she asked herself.

Then it hit her: The worlds greatest puzzle was staring her in the face. Stuck at home, all she had to work with was her brain and her laptop. Maybe they were enough. Chan fired up the kettle for the first of what would become hundreds of cups of tea, stacked four boxes on her kitchen counter to raise her laptop to the proper height, pulled back her long dark hair, and began reading all of the scientific literature she could find on the coronavirus.

It wasnt long before she came across an article about the remarkable stability of the virus, whose genome had barely changed from the earliest human cases, despite trillions of replications. This perplexed Chan. Like many emerging infectious diseases, COVID-19 was thought to be zoonoticit originated in animals, then somehow found its way into people. At the time, the Chinese government and most scientists insisted the jump had happened at Wuhans seafood market, but that didnt make sense to Chan. If the virus had leapt from animals to humans in the market, it should have immediately started evolving to life inside its new human hosts. But it hadnt.

On a hunch, she decided to look at the literature on the 2003 SARS virus, which had jumped from civets to people. Bingo. A few papers mentioned its rapid evolution in its first months of existence. Chan felt the familiar surge of puzzle endorphins. The new virus really wasnt behaving like it should. Chan knew that delving further into this puzzle would require some deep genetic analysis, and she knew just the person for the task. She opened Google Chat and fired off a message to Shing Hei Zhan. He was an old friend from her days at the University of British Columbia and, more important, he was a computational god.

Do you want to partner on a very unusual paper? she wrote.

Sure, he replied.

One thing Chan noticed about the original SARS was that the virus in the first human cases was subtly differenta few dozen letters of genetic codefrom the one in the civets. That meant it had immediately morphed. She asked Zhan to pull up the genomes for the coronaviruses that had been found on surfaces in the Wuhan seafood market. Were they at all different from the earliest documented cases in humans?

Zhan ran the analysis. Nope, they were 100 percent the same. Definitely from humans, not animals. The seafood-market theory, which Chinese health officials and the World Health Organization espoused in the early days of the pandemic, was wrong. Chans puzzle detectors pulsed again. Shing, she messaged Zhan, this paper is going to be insane.

In the coming weeks, as the spring sun chased shadows across her kitchen floor, Chan stood at her counter and pounded out her paper, barely pausing to eat or sleep. It was clear that the first SARS evolved rapidly during its first three months of existence, constantly fine-tuning its ability to infect humans, and settling down only during the later stages of the epidemic. In contrast, the new virus looked a lot more like late-stage SARS. Its almost as if were missing the early phase, Chan marveled to Zhan. Or, as she put it in their paper, as if it was already well adapted for human transmission.

That was a profoundly provocative line. Chan was implying that the virus was already familiar with human physiology when it had its coming-out party in Wuhan in late 2019. If so, there were three possible explanations.

Perhaps it was just staggeringly bad luck: The mutations had all occurred in an earlier host species, and just happened to be the perfect genetic arrangement for an invasion of humanity. But that made no sense. Those mutations would have been disadvantageous in the old host.

Maybe the virus had been circulating undetected in humans for months, working out the kinks, and nobody had noticed. Also unlikely. Chinas health officials would not have missed it, and even if they had, theyd be able to go back now through stored samples to find the trail of earlier versions. And they werent coming up with anything.

That left a third possibility: The missing phase had happened in a lab, where the virus had been trained on human cells. Chan knew this was the third rail of potential explanations. At the time, conspiracy theorists were spinning bioweapon fantasies, and Chan was loath to give them any ammunition. But she also didnt want to play politics by withholding her findings. Chan is in her early thirties, still at the start of her career, and an absolute idealist about the purity of the scientific process. Facts were facts.

Or at least they used to be. Since the start of the pandemic, the Trump administration has been criticized for playing fast and loose with factsdenying, exaggerating, or spinning them to suit the presidents political needs. As a result, many scientists have learned to censor themselves for fear that their words will be misrepresented. Still, Chan thought, if she were to sit on scientific research just to avoid providing ammunition to conspiracy theorists or Trump, would she be any better than them?

Chan knew she had to move forward and make her findings public. In the final draft of her paper, she torpedoed the seafood-market theory, then laid out a case that the virus seemed curiously well adapted to humans. She mentioned all three possible explanations, carefully wording the third to emphasize that if the novel coronavirus did come from a lab, it would have been the result of an accident in the course of legitimate research.

On May 2, Chan uploaded the paper to a site where as-yet-unpublished biology papers known as preprints are shared for open peer review. She tweeted out the news and waited. On May 16, the Daily Mail, a British tabloid, picked up her research. The very next day, Newsweek ran a story with the headline Scientists Shouldnt Rule Out Lab as Source of Coronavirus, New Study Says.

And that, Chan says, is when shit exploded everywhere.

Alina Chan, a molecular biologist at the Broad Institute, says we cant rule out the possibility that the novel coronavirus originated in a labeven though she knows its a politically radioactive thing to say. / Photo by Mona Miri

Chan had come to my attention a week before the Newsweek story was published through her smart and straightforward tweets, which I found refreshing at a time when most scientists were avoiding any serious discussion about the possibility that COVID-19 had escaped from a biolab. Id written a lot about genetic engineering and so-called gain-of-function researchthe fascinating, if scary, line of science in which scientists alter viruses to make them more transmissible or lethal as a way of assessing how close those viruses are to causing pandemics. I also knew that deadly pathogens escape from biolabs with surprising frequency. Most of these accidents end up being harmless, but many researchers have been infected, and people have died as a result.

For years, concerned scientists have warned that this type of pathogen research was going to trigger a pandemic. Foremost among them was Harvard epidemiologist Marc Lipsitch, who founded the Cambridge Working Group in 2014 to lobby against these experiments. In a series of policy papers, op-eds, and scientific forums, he pointed out that accidents involving deadly pathogens occurred more than twice a week in U.S. labs, and estimated that just 10 labs performing gain-of-function research over a 10-year period would run a nearly 20 percent risk of an accidental release. In 2018, he argued that such a release could lead to global spread of a virulent virus, a biosafety incident on a scale never before seen.

Thanks in part to the Cambridge Working Group, the federal government briefly instituted a moratorium on such research. By 2017, however, the ban was lifted and U.S. labs were at it again. Today, in the United States and across the globe, there are dozens of labs conducting experiments on a daily basis with the deadliest known pathogens. One of them is the Wuhan Institute of Virology. For more than a decade, its scientists have been discovering coronaviruses in bats in southern China and bringing them back to their lab in Wuhan. There, they mix genes from different strains of these novel viruses to test their infectivity in human cells and lab animals.

When word spread in January that a novel coronavirus had caused an outbreak in Wuhanwhich is a thousand miles from where the bats that carry this lineage of viruses are naturally foundmany experts were quietly alarmed. There was no proof that the lab was the source of the virus, but the pieces fit.

Despite the evidence, the scientific community quickly dismissed the idea. Peter Daszak, president of EcoHealth Alliance, which has funded the work of the Wuhan Institute of Virology and other labs searching for new viruses, called the notion preposterous, and many other experts echoed that sentiment.

That wasnt necessarily what every scientist thought in private, though. They cant speak directly, one scientist told me confidentially, referring to the virology communitys fear of having their comments sensationalized in todays politically charged environment. Many virologists dont want to be hated by everyone in the field.

There are other potential reasons for the pushback. Theres long been a sense that if the public and politicians really knew about the dangerous pathogen research being conducted in many laboratories, theyd be outraged. Denying the possibility of a catastrophic incident like this, then, could be seen as a form of career preservation. For the substantial subset of virologists who perform gain-of-function research, Richard Ebright, a Rutgers microbiologist and another founding member of the Cambridge Working Group, told me, avoiding restrictions on research funding, avoiding implementation of appropriate biosafety standards, and avoiding implementation of appropriate research oversight are powerful motivators. Antonio Regalado, biomedicine editor of MIT Technology Review, put it more bluntly. If it turned out COVID-19 came from a lab, he tweeted, it would shatter the scientific edifice top to bottom.

Thats a pretty good incentive to simply dismiss the whole hypothesis, but it quickly amounted to a global gaslighting of the mediaand, by proxy, the public. An unhealthy absolutism set in: Either you insisted that any questions about lab involvement were absurd, or you were a tool of the Trump administration and its desperation to blame China for the virus. I was used to social media pundits ignoring inconvenient or politically toxic facts, but Id never expected to see that from some of our best scientists.

Which is why Chan stood out on Twitter, daring to speak truth to power. It is very difficult to do research when one hypothesis has been negatively cast as a conspiracy theory, she wrote. Then she offered some earnest advice to researchers, suggesting that most viral research should be done with neutered viruses that have had their replicating machinery removed in advance, so that even if they escaped confinement, they would be incapable of making copies of themselves. When these precautions are not followed, risk of lab escape is exponentially higher, she explained, adding, I hope the pandemic motivates local ethics and biosafety committees to think carefully about how they can reduce risk. She elaborated on this in another tweet several days later: Id alsopersonallyprefer if high biosafety level labs were not located in the most populous cities on earth.

How Safe Are Bostons Biolabs?

As one of the world centers of biotech, the Hub is peppered with academic and corporate labs doing research on pathogens. Foremost among them is Boston Universitys National Emerging Infectious Diseases Laboratories (NEIDL), the only lab in the city designated as BSL-4 (the highest level of biosafety and the same level as the Wuhan Institute of Virology). It is one of just a dozen or so in the United States equipped to work with live versions of the worlds most dangerous viruses, including Ebola and Marburg. Researchers there began doing so in 2018 after a decade of controversy: Many locals objected to the risks of siting such a facility in the center of a major metropolitan area.

The good news? Before opening, NEIDL undertook one of the most thorough risk assessments in history, learning from the mistakes of other facilities. Even Lynn Klotz, a senior science fellow at the Washington, DCbased Center for Arms Control and Non-Proliferation, who advised local groups that opposed NEIDL, told the medical website Contagion that the lab likely has the best possible security protocols and measures in place.

But the reality, Klotz added, is that most lab accidents are caused by human error, and there is only so much that can be done through good design and protocols to proactively prevent such mistakes. (Or to guard against an intentional release by a disgruntled researcher, as allegedly happened in the anthrax attacks of 2001.) Rutgers molecular biologist Richard Ebright, a longtime critic of potentially dangerous pathogen research, says the risks introduced by NEIDL are not low enough and definitely not worth the negligible benefits.

Still, risk is relative. Klotz has estimated the chance of a pathogen escape from a BSL-4 lab at 0.3 percent per year, and NEIDL is probably significantly safer than the typical BSL-4 lab. And if catching a deadly pathogen is your fear, well, currently you run a good risk of finding one in your own neighborhood. Until that gets cleared up, the citys biolabs are probably among the safer spaces in town.

Chan had started using her Twitter account this intensely only a few days earlier, as a form of outreach for her paper. The social platform has become the way many scientists find out about one anothers work, and studies have shown that attention on Twitter translates to increased citations for a paper in scientific literature. But its a famously raw forum. Many scientists are not prepared for the digital storms that roil the Twitterverse, and they dont handle it well. Chan dreaded it at first, but quickly took to Twitter like a digital native. Having Twitter elevates your work, she says. And I think its really fun to talk to nonscientists about that work.

After reading her tweets, I reviewed her preprint, which I found mind-blowing, and wrote her to say so. She thanked me and joked that she worried it might be career suicide.

It wasnt long before it began to look like she might be right.

Speaking her mind, it turns outeven in the face of censurewas nothing new for Chan, who is Canadian but was raised in Singapore, one of the more repressive regimes on earth. Her parents, both computer science professionals, encouraged free thinking and earnest inquiry in their daughter, but the local school system did not. Instead, it was a pressure-cooker of a system that rewarded students for falling in line, and moved quickly to silence rebels.

That was a bad fit for Chan. You have to bow to teachers, she says. Sometimes teachers from other classes would show up and ask me to bow to them. And I would say, No, youre not my teacher. Back then they believed in corporal punishment. A teacher could just take a big stick and beat you in front of the class. I got whacked so many times.

Still, Chan rebelled in small ways, skipping school and hanging out at the arcade. She also lost interest in her studies. I just really didnt like school. And I didnt like all the extracurriculars they pack you with in Singapore, she says. That changed when a teacher recruited her for math Olympiads, in which teams of students compete to solve devilishly hard arithmetic puzzles. I really loved it, she says. You just sit in a room and think about problems.

Chan might well have pursued a career in math, but then she came up against teams from China in Olympiad competitions. They would just wipe everyone else off the board, she says. They were machines. Theyd been trained in math since they could walk. Theyd hit the buzzer before you could even comprehend the question. I thought, Im not going to survive in this field.

Chan decided to pursue biology instead, studying at the University of British Columbia. I liked viruses from the time I was a teen, she says. I remember the first time I learned about HIV. I thought it was a puzzle and a challenge. That instinct took her to Harvard Medical School as a postdoc, where the puzzle became how to build virus-like biomolecules to accomplish tasks inside cells, and then to Ben Devermans lab at the Broad Institute. When I see an interesting question, I want to spend 100 percent of my time working on it, she says. I get really fixated on answering scientific questions.

Deverman, for his part, says he wasnt actively looking to expand his team when Chan came along, but when opportunities to hire extraordinary people fall in my lap, he takes them. Alina brings a ton of value to the lab, he explains, adding that she has an ability to pivot between different topics and cut to the chase. Nowhere was that more on display than with her coronavirus work, which Deverman was able to closely observe. In fact, Chan ran so many ideas past him that he eventually became a coauthor. She is insightful, determined, and has the rare ability to explain complex scientific findings to other scientists and to the public, he says.

Those skills would prove highly useful when word got out about her coronavirus paper.

If Chan had spent a lifetime learning how to pursue scientific questions, she spent most of the shutdown learning what happens when the answers you come up with are politically radioactive. After the Newsweek story ran, conservative-leaning publications seized on her paper as conclusive evidence that the virus had come from a lab. Everyone focused on the one line, Chan laments. The tabloids just zoomed in on it. Meanwhile, conspiracists took it as hard evidence of their wild theories that there had been an intentional leak.

Chan spent several exhausting days putting out online fires with the many people who had misconstrued her findings. I was so naive, she tells me with a quick, self-deprecating laugh. I just thought, Shouldnt the world be thinking about this fairly? I really have to kick myself now.

Even more troubling, though, were the reactions from other scientists. As soon as her paper got picked up by the media, luminaries in the field sought to censure her. Jonathan Eisen, a well-known professor at UC Davis, criticized the study in Newsweek and on his influential Twitter account, writing, Personally, I do not find the analysis in this new paper remotely convincing. In a long thread, he argued that comparing the new virus to SARS was not enough to show that it was preadapted to humans. He wanted to see comparisons to the initial leap of other viruses from animals to humans.

Moments later, Daszak piled on. The NIH had recently cut its grant to his organization, EcoHealth Alliance, after the Trump administration learned that some of it had gone to fund the Wuhan Institute of Virologys work. Daszak was working hard to get it restored and trying to stamp out any suggestion of a lab connection. He didnt hold back on Chan. This is sloppy research, he tweeted, calling it a poorly designed phylogenetic study with too many inferences and not enough data, riding on a wave of conspiracy to drive a higher impact. Peppering his tweets with exclamation points, he attacked the wording of the paper, arguing that one experiment it cited was impossible, and told Chan she didnt understand her own data. Afterward, a Daszak supporter followed up his thread with a GIF of a mike drop.

It was an old and familiar dynamic: threatened silverback male attempts to bully a junior female member of the tribe. As a postdoc, Chan was in a vulnerable position. The world of science is still a bit medieval in its power structure, with a handful of institutions and individuals deciding who gets published, who gets positions, who gets grants. Theres little room for rebels.

What happened next was neither old nor familiar: Chan didnt back down. Sorry to disrupt mike drop, she tweeted, providing a link to a paper in the prestigious journal Nature that does that exact experiment you thought was impossible. Politely but firmly, she justified each point Daszak had attacked, showing him his mistakes. In the end, Daszak was reduced to arguing that she had used the word isolate incorrectly. In a coup de grce, Chan pointed out that actually the word had come from online data provided by GenBank, the NIHs genetic sequence database. She offered to change it to whatever made sense. At that point, Daszak stopped replying. He insists, however, that Chan is overinterpreting her findings.

With Eisen, Chan readily agreed to test her hypothesis by finding other examples of viruses infecting new hosts. Within days, a perfect opportunity came along when news broke that the coronavirus had jumped from humans to minks at European fur farms. Sure enough, the mink version began to rapidly mutate. You actually see the rapid evolution happening, Chan said. Just in the first few weeks, the changes are quite drastic.

Chan also pointed out to Eisen that the whole goal of a website such as bioRxiv (pronounced bioarchive)where she posted the paperis to elicit feedback that will make papers better before publication. Good point, he replied. Eventually he conceded that there was a lot of interesting analysis in the paper and agreed to work with Chan on the next draft.

The Twitter duels with her powerful colleagues didnt rattle Chan. I thought Jonathan was very reasonable, she says. I really appreciated his expertise, even if he disagreed with me. I like that kind of feedback. It helped to make our paper better.

With Daszak, Chan is more circumspect. Some people have trouble keeping their emotions in check, she says. Whenever I saw his comments, Id just think, Is there something I can learn here? Is there something hes right about that I should be fixing? Ultimately, she decided, there was not.

By late May, both journalists and armchair detectives interested in the mystery of the coronavirus were discovering Chan as a kind of Holmes to our Watson. She crunched information at twice our speed, zeroing in on small details wed overlooked, and became a go-to for anyone looking for spin-free explications of the latest science on COVID-19. It was thrilling to see her reasoning in real time, a reminder of why Ive always loved science, with its pursuit of patterns that sometimes leads to exciting revelations. The website CNET featured her in a story about a league of scientists-turned-detectives who were using genetic sequencing technologies to uncover COVID-19s origins. After it came out, Chan added scientist-turned-detective to her Twitter bio.

Shes lived up to her new nom de tweet. As the search for the source of the virus continued, several scientific teams published papers identifying a closely related coronavirus in pangolinsanteater-like animals that are heavily trafficked in Asia for their meat and scales. The number of different studies made it seem as though this virus was ubiquitous in pangolins. Many scientists eagerly embraced the notion that the animals might have been the intermediate hosts that had passed the novel coronavirus to humans. It fit their preexisting theories about wet markets, and it would have meant no lab had been involved.

As Chan read the pangolin papers, she grew suspicious. The first one was by a team that had analyzed a group of the animals intercepted by anti-smuggling authorities in southern China. They found the closely related virus in a few of them, and published the genomes for that virus. Some of the other papers, though, were strangely ambiguous about where their data was coming from, or how their genomes had been constructed. Had they really taken samples from actual pangolins?

Once again, Chan messaged Shing Hei Zhan. Shing, somethings weird here, she wrote. Zhan pulled up the raw data from the papers and compared the genomes they had published. Individual copies of a virus coming from different animals should have small differences, just as individuals of a species have genetic differences. Yet the genomes in all of the pangolin papers were perfect matchesthe authors were all simply using the first groups data set. Far from being ubiquitous, the virus had been found only in a few pangolins who were held together, and it was unclear where they had caught it. The animals might have even caught it from their own smuggler.

Remarkably, one group of authors in Nature even appeared to use the same genetic sequences from the other paper as if it were confirmation of their own discovery. These sequences appear to be from the same virus (Pangolin-CoV) that we identified in the present study.

Chan called them out on Twitter: Of course its the same Pangolin-CoV, you used the same dataset! For context, she later added, Imagine if clinical trials were playing fast and loose with their patient data; renaming patients, throwing them into different datasets without clarification, possibly even describing the same patient multiple times across different studies unintentionally.

She and Zhan posted a new preprint on bioRxiv dismantling the pangolin papers. Confirmation came in June when the results of a study of hundreds of pangolins in the wildlife trade were announced: Not a single pangolin had any sign of a coronavirus. Chan took a victory lap on Twitter: Supports our hypothesis all this time. The pangolin theory collapsed.

Chan then turned her Holmesian powers on bigger game: Daszak and the Wuhan Institute of Virology. Daszak had been pleading his case everywhere from 60 Minutes to the New York Times and has been successful in rallying sympathy to his cause, even getting 77 Nobel laureates to sign a letter calling for the NIH to restore EcoHealth Alliances funding.

In several long and detailed tweetorials, Chan began to cast a cloud of suspicion on the WIVs work. She pointed out that scientists there had discovered a virus that is more than 96 percent identical to the COVID-19 coronavirus in 2013 in a mineshaft soon after three miners working there had died from a COVID-like illness. The WIV didnt share these findings until 2020, even though the goal of such work, Chan pointed out, was supposedly to identify viruses with the potential to cause human illnesses and warn the world about them.

Even though that virus had killed three miners, Daszak said it wasnt considered a priority to study at the time. We were looking for SARS-related virus, and this one was 20 percent different. We thought it was interesting, but not high risk. So we didnt do anything about it and put it in the freezer, he told a reporter from Wired. It was only in 2020, he maintained, that they started looking into it once they realized its similarity to COVID-19. But Chan pointed to an online database showing that the WIV had been genetically sequencing the mine virus in 2017 and 2018, analyzing it in a way they had done in the past with other viruses in preparation for running experiments with them. Diplomatic yet deadpan, she wrote, I think Daszak was misinformed.

For good measure, almost in passing, Chan pointed out a detail no one else had noticed: COVID-19 contains an uncommon genetic sequence that has been used by genetic engineers in the past to insert genes into coronaviruses without leaving a trace, and it falls at the exact point that would allow experimenters to swap out different genetic parts to change the infectivity. That same sequence can occur naturally in a coronavirus, so this was not irrefutable proof of an unnatural origin, Chan explained, only an observation. Still, it was enough for one Twitter user to muse, If capital punishment were as painful as what Alina Chan is doing to Daszak/WIV regarding their story, it would be illegal.

Daszak says that indeed he had been misinformed and was unaware that that virus found in the mine shaft had been sequenced before 2020. He also says that a great lab, with great scientists, is now being picked apart to search for suspicious behavior to support a preconceived theory. If you believe, deep down, something fishy went on, then what you do is you go through all the evidence and you try to look for things that support that belief, he says, adding, That is not how you find the truth.

Many of the points in Chans tweetorials had also been made by others, but she was the first reputable scientist to put it all together. That same week, Londons Sunday Times and the BBC ran stories following the same trail of breadcrumbs that Chan had laid out to suggest that there had been a coverup at the WIV. The story soon circulated around the world. In the meantime, the WIV has steadfastly denied any viral leak. Lab director Yanyi Wang went on Chinese television and described such charges as pure fabrication, and went on to explain that the bat coronavirus from 2013 was so different than COVID that it could not have evolved into it this quickly and that the lab only sequenced it and didnt obtain a live virus from it.

To this day, there is no definitive evidence as to whether the virus occurred naturally or had its origins in a lab, but the hypothesis that the Wuhan facility was the source is increasingly mainstream and the science behind it can no longer be ignored. And Chan is largely to thank for that.

In late spring, Chan walked through the tall glass doors of the Broad Institute for the first time in months. As she made her way across the gleaming marble foyer, her sneaker squeaks echoed in the silence. It was like the zombie apocalypse version of the Broad; all the bright lights but none of the people. It felt all the weirder that she was wearing her gym clothes to work.

A few days earlier, the Broad had begun letting researchers back into their labs to restart their projects. All computer work still needed to be done remotely, but bench scientists such as Chan could pop in just long enough to move along their cell cultures, provided they got tested for the virus every four days.

In her lab, Chan donned her white lab coat and took inventory, throwing out months of expired reagents and ordering new materials. Then she rescued a few samples from the freezer, took her seat at one of the tissue-culture hoodsstainless steel, air-controlled cabinets in which cell engineers do their workand began reviving some of her old experiments.

She had mixed emotions about being back. It felt good to free her gene-therapy projects from their stasis, and she was even more excited about the new project she and Deverman were working on: an online tool that allows vaccine developers to track changes in the viruss genome by time, location, and other characteristics. It came out of my personal frustration at not being able to get answers fast, she says.

On the other hand, she missed being all-consumed by her detective work. I wanted to stop after the pangolin preprint, she says, but this mystery keeps drawing me back in. So while she waits for her cell cultures to grow, shes been sleuthing on the sideonly this time she has more company: Increasingly, scientists have been quietly contacting her to share their own theories and papers about COVID-19s origins, forming something of a growing underground resistance. Theres a lot of curiosity, she says. People are starting to think more deeply about it. And they have to, she says, if we are going to prevent future outbreaks: Its really important to find out where this came from so it doesnt happen again.

That is what keeps Chan up at nightthe possibility of new outbreaks in humans from the same source. If the virus emerged naturally from a bat cave, there could well be other strains in existence ready to spill over. If they are closely related, whatever vaccines we develop might work on them, too. But that might not be the case with manipulated viruses from a laboratory. Someone could have been sampling viruses from different caves for a decade and just playing mix-and-match in the lab, and those viruses could be so different from one another that none of our vaccines will work on them, she says. Either way, We need to find where this came from, and close it down.

Whatever important information she finds, we can be sure Chan will share it with the world. Far from being shaken by the controversy her paper stirred, she is more committed than ever to holding a line that could all too easily be overrun. Scientists shouldnt be censoring themselves, she says. Were obliged to put all the data out there. We shouldnt be deciding that its better if the public doesnt know about this or that. If we start doing that, we lose credibility, and eventually we lose the publics trust. And thats not good for science. In fact, it would cause an epidemic of doubt, and that wouldnt be good for any of us.

Read the original post:
Was COVID-19 Manmade? Meet the Scientist Behind the Theory - Boston magazine

Read More...

New study by ICGEB-Emory Vaccine Center offers hope to improve Indias plasma therapy regimen – Express Healthcare

September 15th, 2020 10:58 am

Study highlights role of IgG antibodies that bind to the receptor binding domain (RBD) of the SARS-CoV-2, and not the IgG antibodies that bind to the whole viral protein mix, as an excellent surrogate measurement to estimate neutralising antibodies

While intensive efforts continue to focus on development of an effective vaccine, anti-viral or other therapeutic entity, plasma therapy is currently being widely explored as an interim strategy to treat COVID-19.

A recent study by ICMR while raising the lack of benefits from plasma therapy, has highlighted the urgent need for prior measurement of neutralising antibody titres in donors and participants, which may better aid in delineating the role of plasma therapy in management of COVID-19.

Neutralising antibodies, typically of IgG subclass that can potentially block viral infection, are key components for the success of plasma therapy and titers of >320 are generally considered most suitable for successful plasma therapy. Currently, however, mere presence of IgG antibody, regardless of its neutralising ability, is used as a selection criterion for donor convalescent plasma because assessment of neutralising antibodies in routine clinical samples remains a challenge.

Thus, it is important to note that we have insufficient knowledge to understand whether all donors had sufficient titers of neutralising antibodies to donate plasma, and whether these titers reflected in all recipients that received the transfusion.

In this direction, a new ICMR funded study led by Drs Anmol Chandele and Kaja Murali Krishna of ICGEB-Emory Vaccine Center at the International Centre for Genetic Engineering and Biotechnology, in collaboration with ICMR-National Institute of Malaria Research, Department of Biotechnology and the Emory Vaccine Center, Atlanta gives new hope to improve plasma therapy regimen in India1.

This study finds that nearly half of the COVID-19 recovered individuals examined did not have appreciable levels of neutralising antibodies despite having SARS-CoV-2 specific IgG. More importantly, this study finds that it was IgG antibodies that bind to the receptor binding domain (RBD) of the SARS-CoV-2, and not the IgG antibodies that bind to the whole viral protein mix, served as an excellent surrogate measurement to estimate neutralising antibodies. They report that RBD binding IgG titers of more than 1:3000 indicate neutralising antibody levels of more 1:320, a titer which is likely to increase chances of success with plasma therapy.

It is important to note that many Indian government agencies and institutions are already making efforts to bring these RBD-based IgG assays more widely available, and thus this study is very relevant and timely to scientifically validate these efforts. It is notable that the Translational Health Sciences and Technology Institute (THSTI), which is another institute within the Delhi NCR biocluster, has made available an in-house RBD IgG ELISA assay that was recently used for a sero-survey in Pune and very recently RBD IgG assay facility is has been inaugurated in Nagpur.

These basic research efforts currently pursued at the ICGEB-Emory Vaccine Center to understand human immunology of COVID-19 infections in India, gives renewed hope to tailor and improve plasma therapy in India.

References:

Read the original:
New study by ICGEB-Emory Vaccine Center offers hope to improve Indias plasma therapy regimen - Express Healthcare

Read More...

CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS) -…

September 15th, 2020 10:58 am

REHOVOT, Israel, Sept. 14, 2020 /PRNewswire/ --

CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has signed an agreement for distribution of its VergenixFlowable Gel (FG) product in six Commonwealth of Independent States (CIS) countries: Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan.

The Company also reported that it has received the first order in an amount ofhundreds of thousands of U.S. dollars. Based on deal terms, CollPlant will deliver a portion of the order immediately and the remainder over the next six months. The distributor is a Swiss-headquartered pharmaceutical group of companies and the agreement is for a five-year period.

"This distribution agreement will enable new patient populations in the CIS to benefit from Vergenix FG use, which has also already elicited positive feedback in Europe for rapid recovery of chronic wounds," said Yehiel Tal, CEO of CollPlant. "We are proud of the transformative potential of our recombinant human collagen platform technology that facilitates optimal treatment options for patients and remain open to additional collaborations that will bolster commercial infrastructure for Vergenix FG as well as support for our pipeline development efforts. At the same time, we continue to strategically focus on innovative applications of our rhCollagen in medical aesthetics and 3D Bioprinting of organs and tissues. "

Vergenix FG is based on the Company's rhCollagen technology and is a wound-care product designed to treat acute and chronic hard-to-heal wounds, such as diabetic ulcers, pressure sores, surgical cuts and trauma wounds. A single applicationof the product provides an optimized treatment for the healing process until full wound closure.

Recently, a study was publishedin The Diabetic Foot Journal, Vol 23 No 2 2020, byIacopi E et al from the University Hospital in Pisa,Italy. The study demonstrated thatVergenixFG had excellent clinical outcomes inpatientswith post-surgicaldiabetic footwounds. VergenixFG has received CE marking and other regulatory approvals that allow sales and treatments in Europe, Israel and other countries.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and, we believe, are ushering in a new era in regenerative and aesthetic medicine.

Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

In January 2020, we also entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which we and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. Our industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.

For more information about CollPlant, visithttp://www.collplant.com

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements.Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the outbreak of coronavirus; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact atCollPlant:

Eran RotemDeputy CEO & CFOTel: + 972-73-2325600Email: [emailprotected]

Sophia Ononye-Onyia, PhD MPH MBAFounder & CEO, The Sophia Consulting FirmTel: +1-347-851-8674E-mail: [emailprotected]|

SOURCE CollPlant

Home

Read the rest here:
CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS) -...

Read More...

Promoting CRISPR crops at the expense of GMOs is short-sighted when we need both – Genetic Literacy Project

September 15th, 2020 10:58 am

With an ever-growing CRISPR genome-editing toolbox, scientists are creating crops that can resist diseases and pests, withstand global warming, and offer better nutrition. The emergence of this technology offers a crucial opportunity for renewed public engagement around crop engineering. In order to actualize the potential of CRISPR-edited food, we must work together to create and share strategies for productive dialogue. This article identifies one area of necessary improvement in communication and public engagement.

Describing how CRISPR-edited crops are arguably more natural than GMOs, or how these crops could potentially use fewer chemicals than their GMO predecessors reinforces pervasive societal suspicions of GMOs. If we think that engineered crops will play a key role in addressing environmental and public health issues, then promoting CRISPR-edited crops at the expense of GMOs is short-sighted. Instead, we must use CRISPR as a new avenue for renewing productive discourse with the public. CRISPR offers a way to bring everyone back to the table, reintroducing voices into vital conversations that will impact us all.

The question, Is this safe? captures this tension between distancing CRISPR from GMOs in order to separate a new technology from its polarized relative, while not discarding GMOs and avoiding difficult conversations. Science communicators can use the question Is this safe? as a case study to further identify problematic practices and offer strategies for communication alternatives. Before answering this question, we must better understand the consumers decision-making process.

The processes behind engineering a CRISPR-edited crop and a GMO share many commonalities and, in some instances, lead to nearly identical outcomes .

In the wake of an incoming wave of CRISPR-edited crops, communicators have an opportunity to renew conversations surrounding what is natural, and in doing so, address concerns about naturalness and safety. For science communicators, do we suggest that CRISPR-edited crops are more natural? Do we explain how brands with a natural label dont always align with what consumers think they are buying? Or do we do we zoom out and try to separate natural from safe, so we dont tacitly buy into notions that GMOs are all unsafe?

Read the original post

View post:
Promoting CRISPR crops at the expense of GMOs is short-sighted when we need both - Genetic Literacy Project

Read More...

The timeless tale of monarch butterfly migration – centraljersey.com

September 15th, 2020 10:58 am

By Michele S. Byers

Do you ever read through old newspapers and notice that sometimes the topic and perspective are still pretty current and fresh? So much has changed in the world in recent decades, but our fascination with nature is timeless. Please enjoy the following column written 34 years ago by Dave Moore, the former executive director of the New Jersey Conservation Foundation, with a few edits to reflect more recent research and understanding:

Ever notice those bright orange and black butterflies that fly purposefully through our yards and sometimes cluster overnight in trees? They are monarch butterflies, and their flight is purposeful: They are migrating south for the winter.

The monarch butterfly migrates all the way to the mountains of central Mexico, often from as far as New Jersey, New England or nearby Canada. This is one of the most amazing migration stories in nature; one in which the route has been partially realized by naturalists for a long time, but fully understood only a decade ago with the discovery of the long-sought wintering place of the monarchs.

Researchers are still adding to the story. For example, it was at first thought that the same butterflies returned to New Jersey a year after their southward migration. Its now realized that its the grandchildren or even the great-great-great-great grandchildren who come back to the northeast.

Science is still a long way from learning how the butterflies have managed to arrive at the same small area of Mexico over millions of years. But they have, and during their migrations they even congregate on certain trees at specific locations, year after year. These way-points in themselves are popular tourist attractions, as is the Mexican destination.

One butterfly tree of which I am aware stands in Island Beach State Park near Barnegat Lighthouse, and is decorated by thousands of monarchs each autumn. When science finally solves the riddle of the monarchs migration, I suppose a little more magic will have gone out of our lives.

But the danger of lost magic is greater for another reason, and not just in terms of monarch migrations. Can you imagine a world without our common songbirds, or minus many of the larger birds that annually make long round trips south and north?

While we protect them up here, their habitats are being bulldozed and burned away in South America as many countries destroy forests to make way for new development.

The monarchs are lucky; Mexico has set aside their wintering place for tourist and scientific reasons. Not so with the birds.

There are so many plants and animals we know nothing about that are becoming extinct before we can really study them. Fewer than a tenth of the plants, insects and animals on earth have been identified. The rate of extinction is speeding up due to peoples blind exploitation of the environment.

We must do much more to protect reserves where plants and animals can survive in the hope of someday revealing exciting secrets for medicines and foods to help us survive. We must also do a better job of regulating our own chemicals so they dont do us and other life forms in.

Bugs and weeds dont attract as much attention as whales and pandas, but they are equally important in the scheme of things.

Monarch butterflies feed only on milkweed, for example. If we lose the milkweed, we lose the butterfly. And by the way, monarchs have the ability to turn milkweed juice into a toxic substance that has taught predators to avoid them. Other butterflies have learned to mimic monarchs to get the same protection.

With all this loss of life-forms, and with our growing interest in genetic engineering, genetic diversity becomes more important, even as its being threatened. That means we must protect natural areas worldwide, protect native plants and animals, and learn more about the effects of our pesticides and other chemicals before its too late.

You have read about possible links between the herbicide Agent Orange and cancer. Agent Orange contains 2,4-D, a common herbicide. Recent studies point toward a connection between 2,4-D and three cancers in humans, including Hodgkins disease.

Given that everything is connected to everything else, we need to proceed carefully. Not only do we not know who lives in the world with us, but we dont even know what the majority of chemical substances we manufacture are doing to them or us.

Back to Michele: Since Daves nature column was written in September 1986, more research has been done on monarch butterfly migration, as well as on the harmful impacts of many chemical herbicides and pesticides, not just Agent Orange.

The annual journey of monarch butterflies still amazes. In Cape May, the New Jersey Audubon Society now monitors monarch butterflies each fall as they congregate on the peninsula in preparation for their flight across the Delaware Bay. If you get a chance this fall, be sure to visit to see migrating birds and butterflies.

Michele S. Byers is the executive director of the New Jersey Conservation Foundation, Far Hills. She may be reached at info@njconservation.org

Link:
The timeless tale of monarch butterfly migration - centraljersey.com

Read More...

Novavax to Participate in Upcoming Investor Conferences – GlobeNewswire

September 15th, 2020 10:58 am

GAITHERSBURG, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax COVID-19 vaccine candidate, NVX-CoV2373.

Conference details are as follows:

Citi 15th Annual BioPharma Virtual Conference

H.C. Wainwright 22nd Annual Global Investment Conference

Cantor Virtual Global Healthcare Conference

Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Leerink CyberRx Series: Vaccine Forum

A replay of the presentations will also be accessible under the Investors/Events sectionwww.novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.

InvestorsSilvia Taylor and Erika Trahanir@novavax.com240-268-2022

MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659

See the article here:
Novavax to Participate in Upcoming Investor Conferences - GlobeNewswire

Read More...

Investor Interest in Meat Alternative Biotechs… – Labiotech.eu

September 15th, 2020 10:58 am

In recent times, an unexpectedly large number of investments have closed in biotech startups offering sustainable meat alternatives. Why are investors flocking to this field amid a raging pandemic?

Traditional agriculture is a major polluter, especially in the case of meat production. The highest estimations place its share of global greenhouse gas emissions at up to 20%. In an effort to meet the growing demand for sustainability, many biotech companies are developing less energy-intensive sources of protein via fermentation and plant products.

In spite of the financial chaos resulting from the Covid-19 pandemic this year, big money has gone to biotech startups producing meat alternatives. In the US, the prime example is Impossible Foods, which genetically engineers yeast to give plant-based meat alternatives a realistic meat flavor. Last month, Impossible Foods raised a Series G round of 169M ($200M) to accelerate the commercialization of its technology globally.

In Europe, a similar pattern is emerging. The Finnish startup Solar Foods raised a total of 18.5M in a Series A last week. By late 2022, the company plans to launch a protein food ingredient grown from bacteria using electricity, carbon dioxide, water, and nitrogen.

Add to the mix an 8.5M Series A round raised by the German startup Mushlabs, which grows protein-rich mushroom roots via fermentation, and a 19.5M fundraise by Lever VC, a venture firm financing companies developing protein alternatives. Within just a few months, the field has started to blossom.

According to Albrecht Wolfmeyer, International & National Head of the food startup incubator ProVeg, these rounds are just the tip of the iceberg.

Think of precision fermentation and companies like Legendairy in Germany, Remilk in Israel, or Perfect Day in the US, which just raised 254.3M ($300M) in its Series C, Wolfmeyer said. In Europe, the investment rounds are still way smaller but they are growing along with the enthusiasm.

There are several reasons behind this funding surge, said Nick Cooney, founder and Managing Partner of Lever VC. For example, more startups in the field are emerging than ever. And as the first wave of products establish themselves in the market, investors get encouraged to join the party.

In my freezer, I have pints of ice cream from the grocery store that have real whey in them produced via fermentation, without the need for live animals the whey comes from US-based Perfect Day, noted Cooney.

Pasi Vainikka, co-founder and CEO of Solar Foods, likened the situation to the rise of the digital tech sector at the turn of the 21st century. The development of the first mobile devices was basically laying the foundations for a new industrial sector in the global economy, Vainikka explained. I can see the same with food now.

What is most remarkable is that all of this progress comes in spite of the fact that the pandemic threatens economic recessions around the world.

Covid-19 didnt turn out to be as destructive to the food innovation and investment ecosystem as we first thought, said Wolfmeyer. Investors were not as reluctant as expected but mostly rather bullish.

As food companies, they are all deemed essential businesses so never had to pause operations or stop going into the lab, added Cooney.

In fact, dramatic rises were seen in the sales of vegan and plant-based alternatives to meat and dairy products during the pandemic, and they remain high. This surge in demand even outweighed increasing sales of traditional meat and dairy products seen during the hamster shopping season in Spring, said Cooney.

While the field in general seemed robust in the face of pandemic uncertainty, Wolfmeyer and Cooney saw some food biotech startups falling through the gaps, especially those that depended on providing food services. The ProVeg Incubator, for example, advised early-stage startups on how to tighten their belts and apply for governmental support.

What has also become clear this year is that startups making meat alternatives could also strengthen protein supplies during the uncertain times of the pandemic.

Weve seen significant disruptions in the conventional meat supply chain, said Caroline Bushnell, Associate Director of Corporate Engagement at the Good Food Institute in a July article by Fast Company. Companies using fermentation- and cell-based production methods could better automate the meat production process and make it more resilient to Covid-19 shutdowns.

Politicians seem to be thinking along similar lines. Theyre opening up new ways to maintain a steady protein supply in the face of future disruption.

Weve also seen in the past six months governments working to move forward with further establishing the regulatory pathway for biotech-based alternative protein products, as a way to diversify the protein supply chain, said Cooney.

The EU has also recently allocated a 550B recovery fund with a focus on green initiatives such as making agriculture more sustainable. These funds could trickle down to biotechs working in the food and cellular agriculture space, though some worry about the lack of precise guidelines on how to spend this funding.

One of the limitations of this growing movement is the strict stance of the European Commission on products containing genetically modified (GM) ingredients. Impossible Foods is currently awaiting an EU decision on whether it will be able to commercialize its products on European soil. Some believe the company might substitute its meat flavoring for a non-GM alternative to speed up the approval.

For many food biotech startups in Europe, though, this anti-GM environment is no hindrance. For example, Solar Foods doesnt require the use of genetically modified organisms, since it uses a natural strain of bacteria found in soil. Similarly, Mushlabs grows mushroom roots in a fermentation system with no need for genetic engineering.

In general, the main obstacles standing in the way of getting lab-grown food into the mainstream are pricing, quality, and public image. Affordable pricing will take time while the startups scale up their technology. Food quality and public image could still have an uphill struggle given the historically mixed reception of fake meat.

Maybe its for companies like ourselves now to prove new products are good enough so that they dont taste like in the past, Vainikka said.

So it must taste good and be equal, or better than, what we have today. Then people will naturally go for it.

Images from Elena Resko and Solar Foods

Read more:
Investor Interest in Meat Alternative Biotechs... - Labiotech.eu

Read More...

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies…

September 15th, 2020 10:58 am

Sept. 14, 2020 12:00 UTC

Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River

Neogenes proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools

Co-founded by renowned T cell engineering expert Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. with investment from cell therapy industry veteran Arie Belldegrun, M.D. FACS

NEW YORK & AMSTERDAM--(BUSINESS WIRE)-- Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and Syncona, with participation from Polaris Partners and Pontifax. Seed investors Vida Ventures, TPG and Two River also participated in the round.

Neogene, a Two River company, was founded in 2018 by a team of world-class cell therapy experts to advance the development of neo-antigen T cell therapies. Carsten Linnemann, Ph.D., Chief Executive Officer of Neogene, and Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute, Oncode Institute and 2020 recipient of the Dutch Research Councils Stevin Award co-founded the Company with individual investments by cell therapy industry veterans Arie Belldegrun, M.D. FACS, founder of Kite Pharma, Inc. and Co-Founder and Executive Chairman of Allogene Therapeutics, Inc. and David Chang, M.D., Ph.D., Co-Founder, President and Chief Executive Officer of Allogene. Dr. Linnemann and Dr. Schumacher previously co-founded T-Cell Factory B.V., a company acquired by Kite Pharma in 2015.

Dr. Schumacher, an internationally leading immunologist in the areas of neo-antigen biology and T cell engineering, developed the seminal concepts of Neogenes proprietary technology. Neogenes platform allows for the isolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The Companys proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale. The isolated TCR genes are subsequently engineered into T cells of cancer patients to provide large numbers of potent T cells for therapy.

Neogene is committed to forging a path for new fully personalized engineered T cell therapies in solid cancer that are redirected towards neo-antigens found on cancer cells, said Dr. Linnemann. While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, the industry has struggled to translate this success to the enormous unmet need in patients with advanced solid tumors. We believe that through a fully individualized approach using patient-specific TCRs to target neo-antigens, engineered T cell therapy can become broadly accessible to these patients. We are excited that our vision is shared by an outstanding syndicate of marquee investors, who have a deep understanding of and commitment towards the development of novel cell therapies in oncology.

Neo-antigens represent ideal targets for cancer therapy, as they inevitably arise from DNA mutations that enable tumor development in the first place. Further supporting this concept is clear, correlative evidence linking T cell reactivity against neo-antigens with tumor regression in several patients, said Dr. Schumacher. The Neogene platform makes it possible to exploit the neo-antigen reactive TCRs that are present in TIL without a requirement for viable tumor material. In addition, its syn-bio based approach offers major advantages with respect to standardization and scalability and will be critical to achieve our goal of bringing personalized engineered T cell therapies to patients.

In this Series A financing, Neogene expands its distinguished investor base with leading health-care investors from both the U.S. and Europe. For the seed-investors Vida Ventures, TPG and Two River, Neogene marks the second major collaboration in the cell therapy space after the launch of Allogene Therapeutics in 2018. Neogenes seed-financing in 2019 enabled the Company to achieve proof-of-concept for its neo-antigen technology platform and built on the respective expertise of Vida Ventures, Two River and TPG in the gene and cell therapy space.

We believe that Neogenes technology and therapeutic approach has the potential to become a game changer for the treatment of cancer, said Oleg Nodelman, Founder and Managing Director of EcoR1 Capital. We are impressed by the bold vision of the management team and are thrilled to support Neogene as it advances its mission of developing novel therapies for cancer patients in need.

Neogenes approach perfectly aligns with Jeitos mission. Jeito was launched recently to support new and established entrepreneurs aspiring to help patients in need by pioneering novel, ground-breaking medicines underlined by highest quality innovation, said Rafale Tordjman, Founder and Chief Executive Officer at Jeito Capital. We are delighted to welcome Neogene as the first investment into our new portfolio.

We are excited to partner with the outstanding Neogene team, said Martin Murphy, Chief Executive Officer of Syncona. Neogenes technology offers a radically innovative approach to utilize the therapeutic potential of TIL cells by employing state-of-the-art TCR engineering and synthetic biology technologies. Facilitated by the Series A, Neogene intends to further develop its technology with growing offices in Amsterdam and the U.S. with the goal to initiate Phase I clinical studies in 2022.

About Neogene Therapeutics

Neogene Therapeutics, Inc. is a pre-clinical stage biotechnology company pioneering development of next-generation, fully personalized engineered T cells therapies for a broad spectrum of cancers. The Companys engineered T cells target mutated proteins found in cancer cells due to cancer-associated DNA mutations, or neo-antigens, that render tumor cells vulnerable to detection by T cells. Neogenes proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from tumor biopsies. Neogenes novel approach intends to deliver a tailored set of TCR genes for each individual patient, which will be engineered into patient-derived T cells directing them towards neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer.

For more information, please visit http://www.neogene.com, and follow Neogene Therapeutics on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005309/en/

Read the original here:
Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies...

Read More...

Page 382«..1020..381382383384..390400..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick